Business Wire

Aurigene to Present Multiple Programs at the SITC 2018 in Washington D.C. and EORTC-NCI-AACR 2018 in Dublin

Del

Aurigene:

SITC – Nov 7-11, Washington D.C.:

(a) CA-170 - Small molecule oral antagonist of PD-L1/VISTA in Ph-2 (India)
(b) Small molecule oral antagonist of CD47
(c) Small molecule oral antagonist of TIGIT/PD-L1

EORTC-NCI-AACR – Nov 13-16, Dublin:

a. Covalent, highly selective CDK12 inhibitors
b. Degrader of SMARCA2/4
c. Dual antagonists of TIGIT and PD-1 pathways
d. Dual inhibitors of CD73 and A2AR

Details: SITC, Nov 7-11 Washington D.C.

CA-170 Small Molecule Oral Antagonist Targeting PD-L1/VISTA
Title: Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients with advanced solid tumor and Hodgkin lymphoma
Abstract Number: P714
Session Details: Late Breaking
Date & Location: Friday, Nov. 9 from 8 a.m. to 8 p.m. and Saturday, Nov. 10 from 8 a.m. to 8:30 p.m. Hall. E

Small Molecule Oral Antagonist Targeting CD47
Title: Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway
Abstract Number: P529
Session Details: Innate Anti-Tumor Immunity (NK cells, monocytes, macrophages, etc.)
Date & Location: Friday, Nov. 9, from 12:45 – 2:15 p.m. and 6:30 – 8 p.m. Hall E

Small Molecule Oral Antagonist Targeting TIGIT/PD-L1 Pathways
Title: An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity
Abstract Number: P694
Session Details: T-cell Checkpoints and Checkpoint Inhibitors
Date & location: Saturday, Nov. 10 from 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m. Hall E

More details: https://www.sitcancer.org/2018/abstracts/titles

Details of Poster Presentations at EORTC-NCI-AACR, Nov 13-16, Dublin

Covalent Selective CDK12 Inhibitors
Title: Potent anti-tumor activity correlated with inhibition of DNA damage response genes with highly selective and orally bioavailable CDK12 covalent inhibitors
Poster Session: "Drug Design" on 15 November 2018
Poster Time: Thursday 15 November: 10.00-17.30
Poster Abstract Number: 280
Poster Board Number: PB041

SMARCA2/4 Degraders
Title: In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
Poster Session: "Molecular Targeted Agents - PART II" on 16 November 2018
Poster Time: Friday 16 November: 10.00-14.00
Poster Abstract Number: 411
Poster Board Number: PB074

Small Molecule Oral Antagonists Targeting TIGIT/PD-L1 Pathways
Title: Oral immune checkpoint antagonists dually targeting TIGIT and PD-1 pathways for cancer therapy
Poster Session: "Immune Checkpoints" on 14 November 2018
Poster Time: Wednesday 14 November: 10:00-17:30
Poster Abstract Number: 230
Poster Board Number: PB081

Dual Inhibitors of CD73 and A2AR
Title: First-in-class dual inhibitors of CD73 and A2AR for effective suppression of the adenosine signaling pathway to improve anti-tumor immunity
Poster Session: "Late Breaking Poster Presentation" on 13-16 November 2018
Poster Time: Tuesday 13 November: 12.00-18.30; Wednesday 14 November: 10.00-17.30;
Thursday 15 November: 10.00-17.30; Friday 16 November: 10.00-14.00
Poster Abstract Number: LBA17
Poster Board Number: PB220

More details: https://www.ecco-org.eu/Events/ENA2018/Scientific-Programme-and-Abstracts

About Aurigene
Aurigene’s Proprietary Programs business is engaged in discovery and clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene’s pipeline is focused on oral check-point inhibitors, transcriptional CDK inhibitors (CDK7 and CDK12) and protein degraders focused on the chromatin remodeling complex (including SMARCA2/4 degraders). Aurigene’s oral PD-L1/ VISTA antagonist program is currently in Phase 2 (trial initiated by Aurigene in India). Aurigene has initiated a Phase I study for its RORg program for autoimmune diseases in July 2018 and expects to initiate Phase 2 studies by early 2019. Aurigene’s selective CDK7 inhibitor is slated for an IND by Q1 2019 and CDK12 inhibitor by end-2019. More details of our pipeline can be found at: http://www.aurigene.com/proprietary-programs/.

Contact information

Aurigene
Rajshree KT
Senior Director Strategic Alliances
+91–40–44657777
pr@aurigene.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Oxford Nanopore Prevails in Patent Ruling against Pacific Biosciences22.1.2019 17:04Pressemelding

Today the European Patent Office revoked Pacific Biosciences patent EP3045542 with claims to a single molecule sequencing process wherein two strands of DNA are linked by a connecting nucleic acid. The validity of the patent had been challenged by Oxford Nanopore. The EPO ruled that the claims to a single molecule sequencing process were unsupported in the application and that the application only supported a template-directed synthesis sequencing method. As Pacific Biosciences were unwilling to accept this change, the patent was revoked. The decision by the EPO is consistent with a recent decision by the International Trade Commission (ITC) to limit the claims of a related Pacific Biosciences US patent to template-directed synthesis. View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005733/en/ Contact information Oxford Nanopore Zoe McDougall media@nanoporetech.com Website: https://nanoporetech.com/

Värde Partners Names New Partners, Additional Deputy CIO22.1.2019 17:00Pressemelding

Värde Partners is pleased to announce the appointment of Elena Lieskovska and Haseeb Malik to Partner, and the promotion of Brad Bauer to Deputy Chief Investment Officer. “It gives me great pleasure to announce the promotions of three individuals who have been instrumental in the success of our firm through their investing expertise, leadership and integrity,” said George Hicks, Co-Founder and CEO of Värde Partners. “Brad, Elena and Haseeb have all made significant contributions to Värde’s culture, global presence, and, most importantly, delivering returns to our investors.” Based in London, Elena is Head of European Financial Services, responsible for Värde’s private equity investments in specialty finance companies and related businesses in Europe. She joined the firm in 2008 and over the past decade has helped establish the firm as a leader in the consumer finance space, building large credit platforms. Haseeb is Head of Asia Corporate and Traded Credit. Based in Singapore since the

Citi Announces Inaugural Green Bond Issuance22.1.2019 17:00Pressemelding

Citi today announced the issuance of the firm’s first green bond, further enhancing its commitment to environmental and climate finance. The bond will fund renewable energy, sustainable transportation, water quality and conservation, energy efficiency and green building projects financed as part of Citi’s $100 billion Environmental Finance Goal. In the deal, which priced on 22nd January 2019, Citi issued €1 billion 3-year fixed rate notes. The transaction marks the first green bond offering from Citigroup Inc. “We are proud to start the year with the launch of our inaugural green bond,” said Jamie Forese, President of Citigroup and Head of the Institutional Clients Group. “This transaction represents an important next step in expanding Citi’s commitment to sustainable growth. This bond also further enhances our green bond expertise, strengthens our partnerships with clients around the world and responds to increasing investor interest in sustainable finance.” In 2015, Citi announced a

NGINX Has Modernized Full API Lifecycle Management22.1.2019 15:44Pressemelding

NGINX, Inc., the company based on the popular open source project and offering a suite of technologies designed to develop and deliver modern applications, today announced general availability of its API Management Module. The API Management Module for NGINX Controller is part of the NGINX Application Platform, a modular and integrated set of technologies to help organizations create applications with performance, reliability, security, and scale. The NGINX API management solution enables infrastructure and operations (I&O) teams to define and publish APIs, manage traffic to and secure backend applications, monitor performance issues, and analyze API usage. NGINX API Management Module is built on an innovative architecture that provides three unique benefits: Proven – NGINX combines new control-plane functionality with the raw power and efficiency of NGINX Plus, the industry’s most deployed API gateway. NGINX software powers more than 350 million websites and, according to our 2018 use

800 Kilometers Alone across the Largest Freshwater Lake in the World: BWT Supports Extreme Athlete Ernst Bromeis on his Spectacular Swimming Expedition for Environmental Protection22.1.2019 15:39Pressemelding

Clean water is precious. That’s the message that BWT — Europe’s leading water technology company — and extreme athlete Ernst Bromeis hope to spread with a spectacular expedition. Starting July 8, the Swiss athlete will swim 800 kilometers across Lake Baikal, the largest freshwater lake on Earth. BWT will be by his side as initiator and partner for the Lake Baikal project. “We want to give people food for thought and raise awareness of the fact that water is a resource worth protecting. BWT’s water purification solutions help reduce plastic waste and protect the environment with every sip. Consumers can cut their household expenses and do away with the need to lug home water bottles, all while doing their part for the environment. From table water filters to water filter units to faucets and compact water cooler solutions for the home, BWT’s pioneering magnesium technology turns good-quality tap water into outstanding Magnesium Mineralized Water,” says Lutz Hübner, Head of Marketing, BW

Andersen Global Announces Collaboration with Budapest Law Firm22.1.2019 14:30Pressemelding

Andersen Global announced a collaboration agreement with Szabo Kelemen & Partners Attorneys, a respected law firm based in Budapest, Hungary. Hungary marks the 38th country in which Andersen Global offers legal services, expanding the international association’s growing presence in Eastern Europe. Andersen Global is now present in more than 46 countries worldwide. Founded over two decades ago, Szabo Kelemen & Partners began as the legal arm of EY in Hungary. The firm has since grown to be the premier law firm in Budapest. The team is comprised of more than 30 professionals with decades of legal experience and international accolades, and will continue to advise local and international clients on tax, corporate and commercial issues in various industries. “We started as part of the Big Four, and over the last several years, as we’ve watched Andersen Global grow and set the client service bar higher, it was fitting and natural that we join forces to provide our clients with the very best